South Korea-based HanAll Biopharma has announced that Su-jin Park has been appointed as new Co-Chief Executive Officer (CEO). Sean Jeong, who has served as a Co-CEO of HanAll Biopharma since March 2021, will continue to lead HanAll's R&D vision and strategy alongside Park, who will focus on the business strategy and daily operations of HanAll's pharmaceutical business, which generated over 100 billion won in revenue in 2022.

Both CEOs will collaborate in building the organisation and business development to drive HanAll's next phase of growth in both domestic and global markets.  

Park is an experienced executive with a proven track record of driving growth and delivering results in pharmaceutical sales and marketing for more than 20 years. Most recently he tenured as head of the prescription drug (ETC) marketing and sales division in Daewoong Pharmaceutical, where he provided strategic vision and oversight to drive sales for key products, bringing a record-high ETC sales in company's history in 2022 with a successful launching of Fexuclue, a medication for gastroesophageal reflux disease.

As a new Co-CEO, Park will bring his extensive experience and know-how to strengthen HanAll's domestic drug production and sales.